Postoperative Pain Market is Projected to Grow at a CAGR of 7.2% by 2032 | DelveInsight

The dynamics of the postoperative pain market are anticipated to change in the coming years owing to the emerging pipeline including drugs such as APP13007 (Formosa Pharmaceuticals), OCS-01 (Oculis), TLC590 (Taiwan Liposome Company), VX-548 (Vertex Pharmaceuticals), and others, raising awareness of the diseases, incremental healthcare spending worldwide, increase in R&D activities, among others.

New York, USA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- *Postoperative Pain Market is Projected to Grow at a CAGR of 7.2% by 2032 | DelveInsight *

*The dynamics of the postoperative pain market are anticipated to change in the coming years owing to the emerging pipeline including drugs such as APP13007 (Formosa Pharmaceuticals), OCS-01 (Oculis), TLC590 (Taiwan Liposome Company), VX-548 (Vertex Pharmaceuticals), and others, raising awareness of the diseases, incremental healthcare spending worldwide, increase in R&D activities, among others.*

DelveInsight’s *Postoperative Pain Market Insights* report includes a comprehensive understanding of current treatment practices, postoperative pain emerging drugs, market share of individual therapies, and current and forecasted postoperative pain market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

*Key Takeaways from the Postoperative Pain Market Report*

· As per DelveInsight’s analysis, the postoperative pain market size was found to be *USD 2.4 billion* in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
· The total number of incident cases of Postoperative Pain in the 7MM was approximately *78 million* cases in 2022 and is projected to increase during the forecast period (2023-2032), reports DelveInsight.
· Leading postoperative pain companies such as *Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, *and others are developing novel postoperative pain drugs that can be available in the postoperative pain market in the coming years.
· Some of the key therapies for postoperative pain treatment include *TLC590, TPU-006 (Dexmedetomidine Transdermal System [DMTS]), Libvatrep (SAF312), Vocacapsaicin (CA-008), Nepafenac PPDS/Nepafenac Evolute, F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib), SURF-201 (betamethasone 0.2% in KLARITY vehicle), SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%), QUTENZA (8% capsaicin), VX-548, APP13007 (clobetasol propionate ophthalmic nanosuspension), OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%), NTM-001 (ketorolac premixed bag), CL-108 (hydrocodone/acetaminophen/promethazine or HYDEXOR)**, *and others. 
· Most of the approved drugs are available for adults. There is a major opportunity for pharmaceutical companies to develop a drug with fewer side effects and greater efficacy for the young population.
· *OLINVYK (oliceridine )* indicated in adults to manage acute pain, can be reimbursed in inpatient and outpatient settings until permanent codes are established. Market access resources are now available to customers who support reimbursement of OLINVYK at 95% of the Average Wholesale Price (AWP) in advance of the pass-through status being decided.

Discover which therapies are expected to grab the postoperative pain market share @ *Postoperative Pain Market Report*

*Postoperative Pain Overview*

Postoperative pain is a temporary condition characterized by an expected increase in overall discomfort subsequent to a surgical procedure. This type of pain is typically short-lived, lasting from a few days to a few months, and is akin to pain resulting from soft tissue damage, such as a sprain or a minor cut. It diminishes gradually as the affected tissues heal. The characteristics of postoperative pain, including its intensity, nature, and duration, are primarily influenced by various factors, notably the site and nature of the surgery, the extent and type of incision, the trauma induced by the procedure, the patient’s physical and mental condition, their approach to managing pain, psychological and pharmaceutical preparation before surgery, the type of anesthesia used, pain management techniques both before and after the operation, the incidence of any surgical complications, and the quality of care during the postoperative phase.

*Postoperative Pain Epidemiology Segmentation*

The postoperative pain epidemiology section provides insights into the historical and current postoperative pain patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The *postoperative pain market report* proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

· Total Number of Surgical Procedures (inpatient and outpatient)  
· Total Number of Incident Cases of Postoperative Pain
· Severity-specific Incident Cases of Postoperative Pain

Download the report to understand which factors are driving postoperative pain epidemiology trends @ *Postoperative Pain Epidemiological Insights*

*Postoperative Pain Treatment Market *

At present, postoperative pain treatment approaches encompass a variety of methods categorized into pharmacologic and non-pharmacological therapies. Pharmacological options comprise analgesics that encompass *opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, corticosteroids, anesthetics, and similar medications*. Additionally, acute pain management involves the use of benzodiazepines, muscle relaxants, antidepressants, alpha-2 agonists, gamma-aminobutyric acid agonists, and cannabinoids. Non-pharmacological therapies encompass acupuncture, psychological strategies such as cognitive behavioral therapy and mindfulness-based stress reduction, chiropractic manipulation, physical therapy, transcutaneous electrical stimulation, massage therapy, exercise, and various complementary and alternative medicine therapies. These approaches collectively adopt the concept of multimodal analgesia.

In the realm of postoperative pain management, substantial shifts have emerged in recent years. There’s a notable trend away from opioid-centric approaches toward more beneficial alternatives. While opioids once held the gold standard in pain management, the spotlight now shines on multimodal analgesia (MMA) models. Prominent organizations such as the US Department of Health and Human Services (USDHHS) are directing attention toward multimodal pain management. MMA offers increased effectiveness while minimizing adverse effects by addressing multiple pain targets with lower doses. Particularly in ambulatory patient care, the MMA model demonstrates its capacity to provide adequate pain relief, facilitating earlier patient discharge.

Learn more about the FDA-approved drugs for postoperative pain @ *Drugs for* *Postoperative Pain Treatment** *

*Key Postoperative Pain Therapies and Companies*

· TLC590: Taiwan Liposome Company (TLC)
· TPU-006 (Dexmedetomidine Transdermal System [DMTS]): Teikoku Pharma USA
· Libvatrep (SAF312): Novartis Pharmaceuticals
· Vocacapsaicin (CA-008): Concentric Analgesics
· Nepafenac PPDS/Nepafenac Evolute: Mati Therapeutics
· F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib): Arthritis Innovation Corporation/MedinCell
· SURF-201 (betamethasone 0.2% in KLARITY vehicle): Surface Ophthalmics
· SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%): Salvat Laboratories
· QUTENZA (8% capsaicin): Grünenthal
· VX-548: Vertex Pharmaceuticals
· APP13007 (clobetasol propionate ophthalmic nanosuspension): Formosa Pharmaceuticals
· OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%): Oculis
· NTM-001 (ketorolac premixed bag): Neumentum Pharmaceuticals
· CL-108 (hydrocodone/acetaminophen/promethazine or HYDEXOR): Charleston Laboratories

To know more about postoperative pain clinical trials, visit @ *Postoperative Pain Treatment Drugs** *

*Postoperative Pain Market Dynamics*

The postoperative pain market dynamics are anticipated to change in the coming years. The increasing emphasis on *research and development*, coupled with growing awareness of multimodal analgesia among clinicians and patients, is driving the demand for enhanced diagnosis and treatment options for postoperative pain. This surge is notably supported by drugs in advanced development stages, such as *APP13007, OCS-01, TLC590, and VX-548*, which are poised to fortify the overall postoperative painmarket. 

The imminent therapies, primarily non-opioids, offer effectiveness comparable to opioids, presenting a promising solution to diminish *opioid reliance and address safety concerns* related to existing opioid medications. With heightened *public awareness*, there’s a profitable opening for therapeutic innovations to propel this postoperative pain market forward. Multimodal treatments, designed to reduce dependence on *singular treatment methods*, hold significant promise. The introduction of such products is set to expand the capacity to effectively manage postoperative pain.

Furthermore, the *postoperative pain pipeline* is very robust; many potential therapies are being investigated for the treatment of postoperative pain, and it is safe to predict that the treatment space will significantly impact the postoperative pain market during the forecast period. Moreover, the *anticipated introduction of emerging therapies* with improved efficacy and a further *improvement in the diagnosis rate* are expected to drive the growth of the postoperative pain market in the 7MM.

However, several factors may impede the growth of the postoperative pain market. The* lack of effective diagnosis* is one of the major weaknesses in the medical field. Postoperative pain can be a difficult medical problem to diagnose and treat, often resulting from *various events or circumstances*, with pain assessment not effectively implemented in many hospitals. 

The *existing trial design guidelines need improvement*, with a focus on specific patient groups rather than just surgical procedures for future approaches. In some cases, patients constantly try to ignore the pain and avoid proper medication, leading to the *deterioration of their condition* into chronic pain, which is caused by a *lack of healing in the damaged tissue*, thus hindering both the diagnosis and treatment process. Furthermore, *strict regulatory requirements* for drug approval and *high treatment costs* pose a threat to the market.

Moreover, postoperative pain treatment poses a *significant economic burden* and disrupts patients’ overall well-being and QOL. Furthermore, the postoperative pain market growth may be offset by *failures and discontinuation of emerging therapies*, *unaffordable pricing*, *market access and reimbursement issues*, and a *shortage of healthcare specialists*. In addition, the *undiagnosed, unreported cases and the unawareness* about the disease may also impact the postoperative pain market growth.

*Postoperative Pain Report Metrics* *Details*
Study Period 2019–2032
Postoperative Pain Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Postoperative Pain Market Size in 2022  USD 2.4 Billion
Key Postoperative Pain Companies Taiwan Liposome Company (TLC), Teikoku Pharma USA, Novartis Pharmaceuticals, Concentric Analgesics, Mati Therapeutics, Arthritis Innovation Corporation, MedinCell, Surface Ophthalmics, Salvat Laboratories, Grünenthal, Vertex Pharmaceuticals, Formosa Pharmaceuticals, Oculis, Neumentum Pharmaceuticals, Charleston Laboratories, and others
Key Postoperative Pain Therapies TLC590, TPU-006 (Dexmedetomidine Transdermal System [DMTS]), Libvatrep (SAF312), Vocacapsaicin (CA-008), Nepafenac PPDS/Nepafenac Evolute, F14 (sustained-release celecoxib)/mdc-CWM (Celecoxib), SURF-201 (betamethasone 0.2% in KLARITY vehicle), SVT-15473 (clobetasol propionate ophthalmic nanoemulsion 0.05%), QUTENZA (8% capsaicin), VX-548, APP13007 (clobetasol propionate ophthalmic nanosuspension), OCS-01 (dexamethasone cyclodextrin nanoparticle ophthalmic suspension 1.5%), NTM-001 (ketorolac premixed bag), CL-108 (hydrocodone/acetaminophen/promethazine or HYDEXOR), and others

*Scope of the **Postoperative Pain** Market Report*

· *Postoperative Pain Therapeutic Assessment: *Postoperative Pain current marketed and emerging therapies
· *Postoperative Pain* *Market Dynamics:* Attribute Analysis of Emerging Postoperative Pain Drugs
· *Competitive Intelligence Analysis:* SWOT analysis and Market entry strategies
· *Unmet Needs, KOL’s views, Analyst’s views, Postoperative Pain Market Access and Reimbursement*

Discover more about postoperative pain drugs in development @ *Postoperative Pain Clinical Trials*

*Table of Contents*

1. Postoperative Pain Market Key Insights
2. Postoperative Pain Market Report Introduction
3. Postoperative Pain Market Overview at a Glance
4. Postoperative Pain Market Executive Summary
5. Disease Background and Overview
6. Postoperative Pain Treatment and Management
7. Postoperative Pain Epidemiology and Patient Population
8. Patient Journey
9. Postoperative Pain Marketed Drugs
10. Postoperative Pain Emerging Drugs
11. Seven Major Postoperative Pain Market Analysis
12. Postoperative Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

*Related Reports*

*Postoperative Pain Epidemiology Forecast*

*Postoperative Pain Epidemiology Forecast – 2032* report delivers an in-depth understanding of the disease, historical and forecasted postoperative pain epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

*Postoperative Pain Pipeline*

*Postoperative Pain Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key postoperative pain companies, including *Concentric Analgesics, Oculis Pharma, Vivozon Pharmaceutical Inc., Haisco Pharmaceutical Group, Jiangsu HengRui Medicine Co., Ltd., Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical, InSitu Biologics,  *among others.

*Postoperative Pain Management Pipeline*

*Postoperative Pain Management** Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key postoperative pain management companies, including *Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical*, among others.

*Postoperative Pain Management Market*

*Postoperative Pain Management** Market Insights, Epidemiology, and Market Forecast **– 2032 *report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key postoperative pain management companies, including *Nevakar, Inc., Flexion Therapeutics, LipoCure, SiteOne Therapeutics, Allay Therapeutics, Bexson Biomedical*, among others.

*Chronic Pain Market*

*Chronic Pain Market Insights, Epidemiology, and Market Forecast **– 2032* report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key chronic pain companies, including *AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Inc., Pfizer, Anika Therapeutics, Inc., Biogen, Tonix Pharmaceuticals, Inc., Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH*, among others.

*Chronic Pain Pipeline*

*Chronic Pain Pipeline Insight **– 2023* report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key chronic pain companies, including *AbbVie, Paradigm Biopharmaceuticals Ltd., Noven Pharmaceuticals, Inc., Pfizer, Anika Therapeutics, Inc., Biogen, Tonix Pharmaceuticals, Inc., Taiwan Liposome Company, Centrexion Therapeutics, Braeburn Pharmaceuticals, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, Vertanical GmbH*, among others.

*About DelveInsight*

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve*.*

*Connect with us on* *LinkedIn**|**Facebook**|**Twitter*

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+1(919)321-6187 

www.delveinsight.com